ReviewJournal of cellular and molecular medicine2026
Current Status of Research on Losartan in Tumour Therapy.
Review in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Biomarker-Driven Strategies for Stromal Reprogramming in Pancreatic Ductal Adenocarcinoma.Cells · 2026Review
- The mechano-immunological landscape in the tumor microenvironment: From mechanical sensing to a new therapeutic paradigm.Materials today. Bio · 2026Review
- The mechano-immunological barrier in fibrosis-associated lung cancer: targeting matrix stiffness and the Piezo1 axis for microenvironment normalization.Frontiers in pharmacology · 2026Review
- Molecular mechanisms of therapeutic resistance in areca nut-associated oral squamous cell carcinoma: the interplay of chronic inflammation and epithelial-mesenchymal transition.Frontiers in oncology · 2026Review
- Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review.Frontiers in pharmacology · 2026Review
- Current Status of Research on Losartan in Tumour Therapy.Journal of cellular and molecular medicine · 2026Review
- Tumor-Promoting Crosstalk of MMP11⁺ Fibroblasts and SPP1⁺ Macrophages Drive Poor Prognosis in Breast Cancer: Integrated Multi-Omics Analysis.ImmunoTargets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Losartan, a widely prescribed antihypertensive agent, has attracted growing interest as a potential adjuvant in cancer therapy due to its affordability, established safety profile and pleiotropic effects. Emerging preclinical evidence demonstrates that losartan can effectively modulate the tumour microenvironment (TME) by inhibiting transforming growth factor-β (TGF-β) signalling, reducing stromal stiffness and improving vascular perfusion. These changes are shown to enhance the delivery and efficacy of chemotherapeutic agents, an effect potentially amplified when combined with nanocarriers by augmenting the enhanced permeability and retention effect. Beyond TME remodelling, losartan has demonstrated anti-tumour activity across various preclinical models, including those of pancreatic, breast and colorectal cancers. Mechanistically, angiotensin II type 1 receptor (AT1R) blockade is reported to modulate key downstream oncogenic pathways, including PI3K/AKT and YAP/TAZ, and to promote vascular normalisation via mechanisms that may include VEGF downregulation, thereby alleviating hypoxia and improving radiotherapy response. Furthermore, evidence suggests losartan remodels the tumour immune landscape by promoting CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.